In the same study, the inclusion of conventional HDRT (12 Gy) targeted at a single tumour significantly heightened the therapeutic effectiveness of low-dose TRT when delivered in conjunction with CTLA-4. This evidence concerns the gene CTLA4 and neoplasm.